Bio + Healthcare

benchling
benchling

Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.

Milestones
  • 2012 Founded
  • 2019 Partnered, Series C
benchling_graphic
delfi
delfi

Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.

Milestones
  • 2019 Founded
  • 2019 Partnered, Seed
Partner
delfi_graphic
encoded_therapeutics-rectangle
encoded_therapeutics-rectangle

Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.

Milestones
  • 2014 Founded
  • 2019 Partnered, Series C
Partner
encoded_therapeutics_graphic
gilead NASDAQ: GILD
gilead

Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.

Milestones
  • 1987 Founded
  • 1987 Incubated by Menlo Ventures
  • 1992 IPO; NASDAQ: GILD
gilead_graphic

H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.

Milestones
  • 2017 Founded
  • 2020 Partnered, Series A
pillpackAcquired by Amazon
pillpack

PillPack is a full-service pharmacy that delivers a better, simpler experience through convenient packaging, modern technology, and personalized service.

Milestones
  • 2013 Founded
  • 2015 Partnered, Series C
  • 2018 Acquired by Amazon
pillpack_graphic
NASDAQ: PLRX

Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Milestones
  • 2015 Founded
  • 2018 Partnered, Series B
  • 2020 IPO; NASDAQ: PLRX
Partner
pliant_therapeutics_graphic
recursion NASDAQ: RXRX
recursion

Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.

Milestones
  • 2013 Founded
  • 2017 Partnered, Series B
  • 2021 IPO; NASDAQ: RXRX
recursion_graphic

Our perspective

Clear all
List view Grid view
Filters
Permeable peptide graphic

Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines

Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.

JPM branding with Greg Yap and Johnny Hu headshots
Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​
Eleos founders
Empowering Behavioral Health Providers With AI: Our Investment in Eleos
Cartwheel Care graphic
Our Investment in Cartwheel: Improving Youth Mental Health
Photo of Mark DePristo, Lucas Nivon, Johnny Hu, and Namrata Anand
Opportunities and Challenges of Applying Generative AI to Designing New Drugs
Riva founders Dag Kittlaus and Tuhin Sinha with Riva logo
Video: Building Riva With Menlo Labs
Evan Feinberg, CEO of Genesis Therapeutics
Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

Video: Reengineering Drug Discovery With Recursion

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna
Ophelia founder Zack Gray
Video: Fighting the Opioid Epidemic With Ophelia
mental health care graphic
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care
Announcing the Digital Health Founder’s Fellowship
Riva Health founders Dag Kittlaus and Tuhin Sinha

Video: Improving Heart Health With Riva

Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.

Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences
Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!
Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines

Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.

June 4, 2024Johnny Hu, Ph.D. and Greg Yap
Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference​

For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.

February 13, 2024Greg Yap, Johnny Hu and Ph.D.
Empowering Behavioral Health Providers With AI: Our Investment in Eleos

Eleos is the leader in CareOps Automation for behavioral health and joins Menlo Ventures’ exciting portfolio of healthcare software and AI companies.

November 8, 2023Steve Sloane, Andreas Vandris and Derek Xiao
Our Investment in Cartwheel: Improving Youth Mental Health

The single greatest health concern facing American kids and teens today is a crisis in mental health.

September 26, 2023Greg Yap and Derek Xiao
Opportunities and Challenges of Applying Generative AI to Designing New Drugs

Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.

August 9, 2023Johnny Hu and Ph.D.
Video: Building Riva With Menlo Labs

Riva Health founders Tuhin Sinha and Dag Kittlaus discuss their critical mission to revolutionize cardiovascular healthcare; their long histories with Menlo partners Greg Yap and Shawn Carolan; how they were introduced to each other; and the whirlwind journey to FDA approval.

May 12, 2023
Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

May 2, 2023Greg Yap
Video: Early Cancer Detection With Delfi

Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.

March 9, 2023Greg Yap
Video: Reengineering Drug Discovery With Recursion

Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.

March 9, 2023Greg Yap, Johnny Hu and Ph.D.
Fighting Cancer Through Early Detection and New Therapies: Menlo’s Investments in Delfi and Opna

Cancer remains one of the leading causes of death in the U.S. and worldwide.

January 11, 2023Johnny Hu and Ph.D.
Video: Fighting the Opioid Epidemic With Ophelia

Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.

December 8, 2022Greg Yap
Carefully Crafted Digital Approaches Can Improve Youths’ Mental Health Care

In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.

December 7, 2022Greg Yap and Derek Xiao
Announcing the Digital Health Founder’s Fellowship

Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship

December 6, 2022Greg Yap
Video: Improving Heart Health With Riva

Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.

November 22, 2022Greg Yap
Our Investment In Qualio: A New Breed of Quality Management System for Life Sciences

Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.

May 25, 2021JP Sanday
Don’t Forget the Pipes! Why Insurtech Infrastructure Is Poised to Be Huge!

Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.

April 27, 2021Steve Sloane
loader.svg